Selegiline, the selective MAO-B inhibitor, was reported more than two decades ago to mitigate gamma radiation or cisplatin-induced apoptosis in nonmalignant human cells, without displaying any protective effect on prostate cancer and bladder carcinoma cells exposed to the same cancer treatment [62]. Here, MAOB is linked to prostate cancer.